Simponi Pen
Simponi Pen is an originator product from Janssen-Cilag AG and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 932.85 to CHF 1'446.85 depending on the pack; the patient co-payment is 10 per cent plus the deductible.
Core data
- Authorisation holder
- Janssen-Cilag AG
- ATC code
- L04AB06
- IT group
- 07.15 Immunosuppressive Stoffe
- Active substances
- Golimumabum
- Preparation type
- Originator product
- On the SL since
- 01/12/2010
- Last price change
- 01/04/2026
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Inj Lös 50 mg/0.5ml | Injektor 0.5 ml | CHF 842.65 | CHF 932.85 | 01/12/2010 | B | 7680613180011 |
| Inj Lös 100 mg/1ml | Injektor 1 ml | CHF 1'315.28 | CHF 1'446.85 | 01/02/2014 | B | 7680613180035 |
Limitation
This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.
The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.
Rheumatoide Arthritis: Zur subcutanen Behandlung der aktiven rheumatoiden Arthritis (nur in Kombination mit Methotrexat), wenn die vorausgegangene antirheumatische Standardtherapie mit krankheitsmodifizierenden Antirheumatika (DMARDs) unzulänglich war.
Psoriasis-Arthritis: Zur subcutanen Behandlung der Psoriasis-Arthritis, wenn die vorausgegangene antirheumatische Standardtherapie mit krankheitsmodifizierenden Antirheumatika (DMARDs) unzulänglich war.
Morbus Bechterew/ Ankylosierende Spondylitis (AS): Zur Behandlung des Morbus Bechterew/ Ankylosierende Spondylitis, wenn die vorausgegangene konventionelle Therapie unzulänglich war.
Moderate bis schwere Colitis ulcerosa: Zur Behandlung erwachsener Patienten mit moderater bis schwerer Colitis ulcerosa, wenn die vorausgegangene konventionelle Therapie (z.B. mit Azathioprin, 6-Mercaptopurin oder Glukokortikoiden) unzulänglich war oder nicht vertragen wurde.
More preparations in this group
FAQ
Is Simponi Pen covered by Swiss health insurance?
Yes, but only under conditions. Simponi Pen is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.
What does Simponi Pen cost in Switzerland?
The public price is the maximum price set by the FOPH and for Simponi Pen ranges from CHF 932.85 to CHF 1'446.85 per pack. The ex-factory price ranges from CHF 842.65 to CHF 1'315.28. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages